JP2010509306A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010509306A5 JP2010509306A5 JP2009535815A JP2009535815A JP2010509306A5 JP 2010509306 A5 JP2010509306 A5 JP 2010509306A5 JP 2009535815 A JP2009535815 A JP 2009535815A JP 2009535815 A JP2009535815 A JP 2009535815A JP 2010509306 A5 JP2010509306 A5 JP 2010509306A5
- Authority
- JP
- Japan
- Prior art keywords
- ansamycin
- pharmaceutically acceptable
- acceptable salt
- represent
- ome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- ATEBXHFBFRCZMA-VXTBVIBXSA-N rifabutin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC(=C2N3)C(=O)C=4C(O)=C5C)C)OC)C5=C1C=4C2=NC13CCN(CC(C)C)CC1 ATEBXHFBFRCZMA-VXTBVIBXSA-N 0.000 claims 16
- 150000001875 compounds Chemical class 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 14
- 206010028980 Neoplasm Diseases 0.000 claims 10
- 229910052731 fluorine Inorganic materials 0.000 claims 9
- 239000007858 starting material Substances 0.000 claims 9
- 201000011510 cancer Diseases 0.000 claims 7
- 238000000034 method Methods 0.000 claims 7
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- 229960000885 rifabutin Drugs 0.000 claims 5
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 238000011282 treatment Methods 0.000 claims 4
- 208000023275 Autoimmune disease Diseases 0.000 claims 3
- 206010017533 Fungal infection Diseases 0.000 claims 3
- 208000031888 Mycoses Diseases 0.000 claims 3
- 230000033115 angiogenesis Effects 0.000 claims 3
- 210000003719 b-lymphocyte Anatomy 0.000 claims 3
- 230000001419 dependent effect Effects 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 201000004792 malaria Diseases 0.000 claims 3
- 230000036210 malignancy Effects 0.000 claims 3
- 230000004770 neurodegeneration Effects 0.000 claims 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims 3
- 230000000069 prophylactic effect Effects 0.000 claims 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 102000003964 Histone deacetylase Human genes 0.000 claims 2
- 108090000353 Histone deacetylase Proteins 0.000 claims 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims 2
- 230000001851 biosynthetic effect Effects 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000011737 fluorine Substances 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- -1 mitoxanthone Chemical compound 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- QPEJHSFTZVMSJH-UHFFFAOYSA-N 3-amino-5-hydroxybenzoic acid Chemical group NC1=CC(O)=CC(C(O)=O)=C1 QPEJHSFTZVMSJH-UHFFFAOYSA-N 0.000 claims 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 claims 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims 1
- 108010006654 Bleomycin Proteins 0.000 claims 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 claims 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 claims 1
- 108010069236 Goserelin Proteins 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 claims 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 229940079156 Proteasome inhibitor Drugs 0.000 claims 1
- 102000001253 Protein Kinase Human genes 0.000 claims 1
- 229940123237 Taxane Drugs 0.000 claims 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 claims 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 229960002932 anastrozole Drugs 0.000 claims 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 229960000397 bevacizumab Drugs 0.000 claims 1
- 229960001561 bleomycin Drugs 0.000 claims 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims 1
- 229960001467 bortezomib Drugs 0.000 claims 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims 1
- 229960004117 capecitabine Drugs 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 229960005395 cetuximab Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 229960000684 cytarabine Drugs 0.000 claims 1
- 229960002448 dasatinib Drugs 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims 1
- 229960001433 erlotinib Drugs 0.000 claims 1
- 229960002949 fluorouracil Drugs 0.000 claims 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims 1
- 235000008191 folinic acid Nutrition 0.000 claims 1
- 239000011672 folinic acid Substances 0.000 claims 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 1
- 229960002584 gefitinib Drugs 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- 229960002913 goserelin Drugs 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims 1
- 229960002411 imatinib Drugs 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 229960004891 lapatinib Drugs 0.000 claims 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims 1
- 229960004942 lenalidomide Drugs 0.000 claims 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 1
- 229960001691 leucovorin Drugs 0.000 claims 1
- 229960004296 megestrol acetate Drugs 0.000 claims 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 238000002625 monoclonal antibody therapy Methods 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000003207 proteasome inhibitor Substances 0.000 claims 1
- 108060006633 protein kinase Proteins 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 229960003787 sorafenib Drugs 0.000 claims 1
- 229960001796 sunitinib Drugs 0.000 claims 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 229960001603 tamoxifen Drugs 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 229960000235 temsirolimus Drugs 0.000 claims 1
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 229960005026 toremifene Drugs 0.000 claims 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
- 229960003048 vinblastine Drugs 0.000 claims 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims 1
- 229960004528 vincristine Drugs 0.000 claims 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims 1
- 229960002066 vinorelbine Drugs 0.000 claims 1
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 claims 1
- 229960000237 vorinostat Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0622342.4A GB0622342D0 (en) | 2006-11-09 | 2006-11-09 | Novel compounds and methods for their production |
| GB0720875A GB0720875D0 (en) | 2007-10-24 | 2007-10-24 | Novel compounds and methods for their production |
| PCT/GB2007/050679 WO2008056188A2 (en) | 2006-11-09 | 2007-11-09 | Novel compounds and methods for their production |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010509306A JP2010509306A (ja) | 2010-03-25 |
| JP2010509306A5 true JP2010509306A5 (enExample) | 2010-12-16 |
Family
ID=39362724
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009535815A Pending JP2010509306A (ja) | 2006-11-09 | 2007-11-09 | 新規化合物及びそれらの製造方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8492370B2 (enExample) |
| EP (1) | EP1973883B1 (enExample) |
| JP (1) | JP2010509306A (enExample) |
| KR (1) | KR20090075856A (enExample) |
| AU (1) | AU2007319014B2 (enExample) |
| BR (1) | BRPI0718564A2 (enExample) |
| CA (1) | CA2669047A1 (enExample) |
| ES (1) | ES2389740T3 (enExample) |
| MX (1) | MX2009004775A (enExample) |
| WO (1) | WO2008056188A2 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010516282A (ja) * | 2007-01-26 | 2010-05-20 | コーサン バイオサイエンシーズ， インコーポレイテッド | 工学的生合成によるマクロラクタム |
| KR101097850B1 (ko) | 2009-02-24 | 2011-12-23 | 한국생명공학연구원 | 젤다나마이신 생합성 조절유전자 변이주 및 이를 이용한 젤다나마이신 생산방법 |
| CN117695374B (zh) * | 2024-01-25 | 2024-09-06 | 超越健康科技(浙江)有限公司 | 一种用于治疗帕金森病的生物药物 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2127457A1 (en) * | 1992-01-06 | 1993-07-22 | Walter P. Cullen | Process and uses for 4,5-dihydrogeldanamycin and its hydroquinone |
| ATE433961T1 (de) | 2002-02-08 | 2009-07-15 | Conforma Therapeutics Corp | Ansamycine mit verbesserten pharmakologischen und biologischen eigenschaften |
| US7282493B2 (en) * | 2003-12-23 | 2007-10-16 | Infinity Pharmaceuticals, Inc. | Analogs of benzoquinone-containing ansamycins and methods of use thereof |
| WO2005061461A1 (ja) | 2003-12-24 | 2005-07-07 | Kyowa Hakko Kogyo Co., Ltd. | ヒートショックプロテイン90（hsp90）ファミリー蛋白質阻害剤 |
| WO2006098761A2 (en) * | 2005-03-11 | 2006-09-21 | The Regents Of The University Of Colorado | Hsp90 inhibitors, methods of making and uses therefor |
| CN101213178A (zh) * | 2005-06-29 | 2008-07-02 | 协和发酵工业株式会社 | 苯环型安莎霉素衍生物 |
| CA2628728A1 (en) | 2005-12-24 | 2007-07-05 | Biotica Technology Ltd. | 21-deoxymacbecin analogues useful as antitumor agents |
| CN101012196A (zh) * | 2006-12-27 | 2007-08-08 | 中国人民解放军军事医学科学院毒物药物研究所 | 芳香化格尔德霉素类衍生物及其制备方法和用途 |
| JP2010516282A (ja) * | 2007-01-26 | 2010-05-20 | コーサン バイオサイエンシーズ， インコーポレイテッド | 工学的生合成によるマクロラクタム |
-
2007
- 2007-11-09 MX MX2009004775A patent/MX2009004775A/es active IP Right Grant
- 2007-11-09 KR KR1020097009593A patent/KR20090075856A/ko not_active Ceased
- 2007-11-09 WO PCT/GB2007/050679 patent/WO2008056188A2/en not_active Ceased
- 2007-11-09 JP JP2009535815A patent/JP2010509306A/ja active Pending
- 2007-11-09 CA CA002669047A patent/CA2669047A1/en not_active Abandoned
- 2007-11-09 AU AU2007319014A patent/AU2007319014B2/en not_active Ceased
- 2007-11-09 BR BRPI0718564-2A patent/BRPI0718564A2/pt not_active IP Right Cessation
- 2007-11-09 US US12/513,967 patent/US8492370B2/en active Active
- 2007-11-09 EP EP07824891A patent/EP1973883B1/en not_active Not-in-force
- 2007-11-09 ES ES07824891T patent/ES2389740T3/es active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102820455B1 (ko) | Shp2 활성 억제용 화합물의 제조 방법 | |
| JP7032583B2 (ja) | アルギナーゼ活性を阻害する組成物及び方法 | |
| AU2015243379B2 (en) | Tubulysin derivatives | |
| CN101641117B (zh) | 药物组合物 | |
| JP7673041B2 (ja) | 治療薬としての細胞毒素のペプチドコンジュゲート | |
| JP6773915B2 (ja) | 前立腺癌を治療する組み合わせ、薬物組成物および治療方法 | |
| JP2019525962A (ja) | ケモカイン受容体調節剤及びそれの使用 | |
| EA038192B1 (ru) | Фармацевтические композиции, содержащие диастереомеры макролида, способы их синтезирования и терапевтическое применение | |
| JP6425653B2 (ja) | 抗腫瘍剤及び抗腫瘍効果増強剤 | |
| CA2994404A1 (en) | Beta-substituted beta-amino acids and analogs as chemotherapeutic agents and uses thereof | |
| JP2019505548A (ja) | Ｍｙｃモジュレーターとしてのｍａｘバインダーおよびこれらの使用 | |
| JP2011517455A (ja) | Ｃ（１０）エチルエステルおよびｃ（１０）シクロプロピルエステル置換タキサン | |
| JP2009536181A5 (enExample) | ||
| EP3101020B1 (en) | Deuterated quinazolinone compound and pharmaceutical composition comprising same | |
| JP2010509306A5 (enExample) | ||
| JPWO2021007435A5 (enExample) | ||
| JP2024542212A (ja) | 治療薬としてのペプチドチューブリン阻害剤のペプチドコンジュゲート | |
| JP2009536934A5 (enExample) | ||
| AU2019318046A1 (en) | Histone demethylase 5 inhibitors and uses thereof | |
| EP3179998B1 (en) | Compounds for the treatment of hpv-induced carcinoma | |
| AU2020343329B2 (en) | Methods of treatment | |
| CN1533273A (zh) | 紫杉烷类药物的节拍式给药 | |
| HK40095791A (en) | Process of manufacture of a compound for inhibiting the activity of shp2 | |
| RU2020138336A (ru) | Ингибиторы рецепторов erbb |